Orion Therapeutics awarded NSF Phase II STTR grant to advance lead asset for restenosis, powered by our GENESYS™ targeted delivery platform
We are excited to announce that Orion Therapeutics has been awarded an NSF Phase II STTR grant to advance our lead asset for restenosis, powered by our GENESYS™ targeted delivery platform. This funding will support studies that both move our asset toward IND-enabling development and further validate the GENESYS™ platform as a lipopeptide-enabled lipid nanoparticle […]
Volunteer 40 Under 40: Recognizing alumni under the age of 40 excelling personally and professionally since completing their degree at UT
Exciting News! Our CEO, Trey Fisher, PhD has been named a 2025 Volunteer 40 Under 40 Award recipient by the University of Tennessee, Knoxville!🎉 We’re grateful for Trey’s leadership and vision as Orion Therapeutics, Inc. advances LNP-RNA delivery and genetic medicine to tackle critical health challenges. His dedication to innovation and patient impact continues to […]